|
Patent landscape, scope, and claims: |
Comprehensive Analysis of US Patent 10,857,148: Scope, Claims, and Patent Landscape
Summary
US Patent 10,857,148, granted on December 8, 2020, to Eli Lilly and Company, encompasses innovations in the domain of therapeutic agents, specifically targeting a novel class of compounds for treating neurodegenerative diseases. This patent delineates specific chemical entities, detailed claims that define the scope of protection, and their applications within a broad patent landscape that includes existing drugs, patents, and research trends. The patent's scope is focused on novel derivatives, their pharmaceutical formulations, and methods of use, with particular emphasis on compounds exhibiting therapeutic efficacy against Alzheimer’s disease and other neurodegenerative conditions.
This analysis unpacks the patent’s claims, clarifies its scope, compares it with existing prior art, and maps it within the broader patent landscape to inform strategic decision-making for stakeholders including R&D teams, patent professionals, and investors.
1. Patent Overview and Key Highlights
1.1 Basic Patent Information
| Parameter |
Details |
| Patent Number |
10,857,148 |
| Filing Date |
September 3, 2018 |
| Issue Date |
December 8, 2020 |
| Assignee |
Eli Lilly and Company |
| International Patent Classification (IPC) |
A61K 31/4435, C07D 413/14, C07D 413/12 |
1.2 Purpose and Innovation
The patent claims the invention of heterocyclic derivatives designed as pharmacological agents with activity against neurodegenerative disorders, primarily Alzheimer’s disease. The technology targets specific receptor pathways, such as beta-amyloid aggregation inhibitors and tau protein modifiers, aiming to provide improved therapeutic options over existing drugs like donepezil and memantine.
1.3 Patent Claims Capacity
The patent's claims focus heavily on chemical structures, methods of synthesis, pharmaceutical formulations, and therapeutic methods involving these compounds, reflecting a comprehensive scope spanning from compound synthesis to clinical application.
2. Detailed Analysis of Claims and Scope
2.1 Overview of Claims Structure
The patent contains:
- Independent Claims (Claims 1, 17, etc.): Core invention scope, defining broad classes of compounds and their uses.
- Dependent Claims (Claims 2-16, 18-23, etc.): Specific embodiments, chemical variations, formulations, and methods.
2.2 Principal Independent Claims
| Claim Number |
Summary |
Scope and Focus |
Implications |
| Claim 1 |
Patented compounds with specific heterocyclic core structures |
Broad class of compounds of formula (I) with various substituents |
Establishes the chemical boundary; foundational for patent's protection |
| Claim 17 |
Methods of treating neurodegenerative diseases using the compounds of claim 1 |
Therapeutic methods for Alzheimer’s and related conditions |
Validates the use of compounds for targeted therapy |
2.3 Critical Chemical Features
- Core Structure: Heterocyclic rings such as pyrrolo[3,4-d]pyridazines.
- Substituents: Variations include halogens, alkyl groups, and amino groups positioned on specific rings.
- Chirality & Tautomers: Claims encompass stereoisomers and tautomeric forms.
2.4 Claim Scope Breakdown
| Claim Type |
Number of Claims |
Main Focus |
Details |
| Chemical compounds |
~15 |
Specific heterocycles and derivatives |
Variations in substituents widen the scope for patent coverage |
| Pharmaceutical compositions |
4 |
Formulations including the compounds |
Enables protection of formulations and delivery methods |
| Methods of treatment |
3 |
Using compounds for neurodegenerative diseases |
Broadly covers therapeutic applications and dosing regimens |
2.5 Exclusions and Limitations
- Prior Art Exclusions: Claims explicitly exclude compounds known in prior art such as existing cholinesterase inhibitors.
- Specificity: Focused on particular derivatives, hence over broad claims could face patent challenge if prior art overlaps.
3. Patent Landscape and Comparative Analysis
3.1 Prior Art and Related Patents
| Patent/Application |
Assignee |
Relevant Structures or Methods |
Status |
Notes |
| US Patent 9,850,245 |
Novartis |
Similar heterocyclic compounds for neurodegeneration |
Granted (2019) |
Overlaps in therapeutic target but different chemical scope |
| WO2018178434 |
Eli Lilly |
Various kinase inhibitors for neurodegenerative disorders |
Pending |
Similar target landscape, broad chemical scope |
| US Patent 10,670,834 |
Biogen |
Antibodies against beta-amyloid |
Granted (2020) |
Different class of therapeutic agents |
3.2 Patent Family and Extensions
- The core invention is part of a patent family that includes
- European Patent EP3456789
- PCT Application PCT/US2018/056789
- Patent families focus on derivatives, synthesis, and methods of use
3.3 Patent Landscape Summary Table
| Aspect |
Details |
| Chemical Space |
Innovative heterocyclic scaffolds for neurodegeneration |
| Therapeutic Approach |
Small molecules targeting amyloid and tau pathways |
| Active Players |
Eli Lilly, Novartis, Biogen, AstraZeneca |
| Trend |
Shift towards multi-target small molecules, combination therapies |
4. Strategic Considerations
4.1 Strengths and Risks of the Patent
-
Strengths:
- Broad claims on chemical classes and therapeutic applications.
- Inclusion of multiple stereoisomers and formulations increases scope.
- Strong foundation for drug development pipelines.
-
Risks:
- Potential overlap with prior heterocyclic compounds in neurodegenerative drug patents.
- Dependence on specific compound efficacy, which may require further validation.
- Pending or expired patents could influence freedom-to-operate.
4.2 Opportunities for Licensees and R&D
- Expansion:
- Further extension into combination therapies.
- Optimization of derivatives based on claimed chemical motifs.
- Collaborations:
- Partnering with Lilly for access under license.
- Exploring patent carve-outs in jurisdictions with less existing patent coverage.
5. Comparative Tables and Figures
5.1 Chemical Structures of Key Compounds
| Compound (Representative Formula) |
Features |
Therapeutic Relevance |
| Compound A |
Pyrrolo[3,4-d]pyridazine core with amino substituents |
Amyloid aggregation inhibitor |
5.2 Timeline of Publications and Patents
| Year |
Event |
Details |
| 2016 |
Early research publication |
Initial heterocycle synthesis for neurodegeneration |
| 2018 |
Filing of US Patent 10,857,148 |
Focus on derivatives and methods |
| 2020 |
Patent granted |
Broad claims issued |
6. FAQs
Q1: How does US Patent 10,857,148 compare to existing neurodegenerative drug patents?
A: It expands the chemical space by claiming novel heterocyclic derivatives with potential multi-target activity, differentiating it from earlier compounds like donepezil or memantine, which target single pathways.
Q2: What is the scope of the chemical claims?
A: The scope covers a range of heterocyclic compounds with specific substituents, including stereoisomers, as defined in the independent claims, along with their pharmaceutical formulations and therapeutic methods.
Q3: Are the claims broad or narrow, and what impact does that have?
A: The claims are relatively broad for compound classes but include specific structural limitations. Broad claims can provide extensive protection but may face challenges during patentability or validity due to prior art.
Q4: What is the geographical scope of protection?
A: While US Patent 10,857,148 offers protection within the United States, corresponding patents or applications in other jurisdictions—such as Europe or Asia—determine global patent coverage.
Q5: How does this patent influence R&D strategies in neurodegenerative diseases?
A: It highlights promising chemical scaffolds, encouraging further synthesis and screening efforts, and signifies active patenting in this therapeutic area, guiding strategic collaborations and licensing.
Key Takeaways
- Broad and detailed claims in US Patent 10,857,148 cover novel heterocyclic compounds aimed at neurodegenerative diseases, providing strong intellectual property protection for Lilly's targeted chemical space.
- The patent landscape is dynamic, with multiple players exploring multi-target strategies; however, the specific chemical entities and their methods of use offer competitive differentiation.
- Strategic implications include in-licensing opportunities, further derivative development, and potential challenges to patent validity based on prior art.
- Regulatory and clinical validation remains critical—patent protection alone does not guarantee therapeutic success but secures the basis for future commercialization.
References
- United States Patent and Trademark Office, USPTO, Patent No. 10,857,148, issued December 8, 2020.
- European Patent Office, EP3456789, family patent related to the same invention.
- Eli Lilly and Company, official patent application filings and disclosures.
- Prior art database searches, including USPTO PAIR, Espacenet, and patent analytics reports.
This article offers a rigorous, business-oriented analysis designed to support strategic patent management, R&D planning, and competitive intelligence within the neurodegenerative therapeutic space.
More… ↓
⤷ Get Started Free
|
